Physician profile
Harry E Mccrea
NPI 1689786477
$1,986.22
in general payments reported to CMS, 2019-2025
24 companies · $21.30 in 2025
The $21.30 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $135 · 2021: $340 · 2022: $545 · 2023: $568 · 2024: $221 · 2025: $21.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $266.41 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $240.72 | 2019-2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $230.03 | 2019-2025 | |
| Amgen INC. | $186.07 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.25 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $118.75 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $112.53 | 2020-2022 | |
| Pfizer INC. | $100.39 | 2020-2024 | |
| Astrazeneca Pharmaceuticals Lp | $96.94 | 2019-2023 | Farxiga |
| Edwards Lifesciences Corporation | $84.97 | 2019-2023 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $54.13 | 2021-2023 | Nexletol |
| Kestra Medical Technology Services, INC. | $48.01 | 2024 | Assure Wcd |
| Scpharmaceuticals INC. | $46.42 | 2023 | |
| Baxter Healthcare | $40.58 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.01 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $34.19 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $27.06 | 2023 | Arcalyst |
| Abiomed | $25.50 | 2019-2020 | |
| Cvrx, INC. | $22.58 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $20.27 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $19.69 | 2023 | Optimizer |
| Novo Nordisk INC | $18.71 | 2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $18.21 | 2024 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $16.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Mccrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.